(Total Views: 491)
Posted On: 10/07/2021 6:09:40 AM
Post# of 154119
Hoops,
Thanks for sharing. Exciting to be working with MD Anderson.
Very appropriate to gain a better understanding of the MOA (lots speculated with what seem to be some open questions).
I hope more clinical trials are forthcoming.
Thanks for sharing. Exciting to be working with MD Anderson.
Very appropriate to gain a better understanding of the MOA (lots speculated with what seem to be some open questions).
I hope more clinical trials are forthcoming.
Quote:
VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced a study for treating triple-negative breast cancer (TNBC) with leronlimab in a humanized TNBC xenograft model. This investigator-initiated study is being led by Jangsoon Lee, Ph.D., assistant professor of Breast Medical Oncology Research at The University of Texas MD Anderson Cancer Center.
(5)
(0)
